Dr. He on Future Treatment for Patients With Hepatocellular Carcinoma

Video

In Partnership With:

Aiwu Ruth He, MD, discusses the combination regimen of bevacizumab and atezolizumab in patients with advanced-stage hepatocellular carcinoma.

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the combination regimen of bevacizumab (Avastin) and atezolizumab (Tecentriq) in patients with advanced-stage hepatocellular carcinoma (HCC).

Results show that patients with HCC who received this combination experienced an improvement in progression-free and overall survival (OS) compared with sorafenib (Nexavar). The median OS for bevacizumab and atezolizumab was not estimable compared with 13.2 months for patients who received sorafenib. Additionally, the median progression-free survival (PFS) with atezolizumab/bevacizumab was 6.8 months compared with 4.3 months for sorafenib.

This combination therapy could become a frontline systemic therapy for advanced-stage HCC, says He. A randomized phase III trial evaluating the combination is ongoing.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,